Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Frontiers in neurology. 2019 Nov 13. doi: 10.3389/fneur.2019.01182. pmc: PMC6863928
    The TOSCA Registry for Tuberous Sclerosis-Lessons Learnt for Future Registry Development in Rare and Complex Diseases.
    Marques R1,  Belousova E2,  Benedik MP3,  Carter T4,  Cottin V5,  Curatolo P6,  Dahlin M7,  D'Amato L8,  Beaure d'Augères G9,  de Vries PJ10,  Ferreira JC11,  Feucht M12,  Fladrowski C13,  Hertzberg C14,  Jansen AC15,  Jozwiak S16,  Kingswood JC17,  Lawson JA18,  Macaya A19,  O'Callaghan F20,  Qin J21,  Sander V22,  Sauter M23,  Shah S24,  Takahashi Y25,  Touraine R26,  Youroukos S27,  Zonnenberg B28,  Nabbout R29
    Author information
    1Novartis Farma S.p.A., Origgio, Italy.
    2Research and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia.
    3SPS Pediatrična Klinika, Ljubljana, Slovenia.
    4Tuberous Sclerosis Association, Nottingham, United Kingdom.
    5Hôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France.
    6Tor Vergata University Hospital, Rome, Italy.
    7Karolinska University Hospital, Stockholm, Sweden.
    8Novartis Farma S.p.A., Origgio, Italy.
    9Association Sclérose Tubéreuse de Bourneville, Gradignan, France.
    10Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa.
    11Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
    12Universitätsklinik für Kinder-und Jugendheilkunde, Vienna, Austria.
    13Associazione Sclerosi Tuberosa ONLUS, Milan, Italy.
    14Vivantes-Klinikum Neukölln, Berlin, Germany.
    15Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel VUB, Brussels, Belgium.
    16Department of Child Neurology, Warsaw Medical University, Warsaw, Poland.
    17Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, United Kingdom.
    18The Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia.
    19Hospital Universitari Vall d'Hebron, Barcelona, Spain.
    20Institute of Child Health, University College London, London, United Kingdom.
    21Department of Pediatrics, Peking University People's Hospital, Beijing, China.
    22Tallinn Children Hospital, Tallinn, Estonia.
    23Klinikverbund Kempten-Oberallgäu gGmbH, Kempten, Germany.
    24Novartis Healthcare Pvt. Ltd., Hyderabad, India.
    25National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO, Shizuoka, Japan.
    26Department of Genetics, CHU-Hôpital Nord, Saint Etienne, France.
    27St. Sophia Children's Hospital, Athens, Greece.
    28University Medical Center, Utrecht, Netherlands.
    29Department of Pediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute, Inserm U1163, Paris Descartes University, Paris, France.
    Abstract

    The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to provide insights into the clinical characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study were to identify issues that arose during the design, execution, and publication phases of TOSCA, and to reflect on lessons learnt that may guide future registries in rare and complex diseases. A questionnaire was designed to identify the strengths, weaknesses, and issues that arose at any stage of development and implementation of the TOSCA registry. The questionnaire contained 225 questions distributed in 7 sections (identification of issues during registry planning, during the operation of the registry, during data analysis, during the publication of the results, other issues, assessment of lessons learnt, and additional comments), and was sent by e-mail to 511 people involved in the registry, including 28 members of the Scientific Advisory Board (SAB), 162 principal investigators (PIs), and 321 employees of the sponsor belonging to the medical department or that were clinical research associate (CRA). Questionnaires received within the 2 months from the initial mailing were included in the analysis. A total of 53 (10.4%) questionnaires were received (64.3% for SAB members, 12.3% for PIs and 4.7% for employees of the sponsor), and the overall completeness rate for closed questions was 87.6%. The most common issues identified were the limited duration of the registry (38%) and issues related to handling of missing data (32%). In addition, 25% of the respondents commented that biases might have compromised the validity of the results. More than 80% of the respondents reported that the registry improved the knowledge on the natural history and manifestations of TSC, increased disease awareness and helped to identify relevant information for clinical research in TSC. This analysis shows the importance of registries as a powerful tool to increase disease awareness, to produce real-world evidence, and to generate questions for future research. However, there is a need to implement strategies to ensure patient retention and long-term sustainability of patient registries, to improve data quality, and to reduce biases.


    Copyright © 2019 Marques, Belousova, Benedik, Carter, Cottin, Curatolo, Dahlin, D'Amato, Beaure d'Augères, de Vries, Ferreira, Feucht, Fladrowski, Hertzberg, Jansen, Jozwiak, Kingswood, Lawson, Macaya, O'Callaghan, Qin, Sander, Sauter, Shah, Takahashi, Touraine, Youroukos, Zonnenberg and Nabbout.

    KEYWORDS: TOSCA, TSC, issues, lessons, registry, strengths, weaknesses

    Publikations ID: 31798515
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt